PE-22-28
- Status
- Preclinical, , not approved for human use
- Evidence
Not graded on a research bench yet
PE-22-28 is a synthetic seven-amino-acid peptide (sequence PAGASRLLLLTGEIDLP derivative, commonly truncated to PE-22-28 as shorthand for "position 22-28" within the parent humanin-family sequence) that was designed as an analog of Humanin with specific interest in activity at glutamate transporter regulation and cytoprotective signaling relevant to depression and neuroprotection.
Reviewed
01Overview
What PE-22-28 is
The peptide emerged from a research program characterizing short analogs of humanin that retain bioactivity while simplifying the structure for synthetic accessibility and potential therapeutic development. PE-22-28 specifically attracted attention when preclinical work suggested antidepressant-like activity in rodent models of depression, with a proposed mechanism involving glial cell modulation and glutamate transporter 1 (GLT-1/EAAT2) regulation. The compound sits in the broader field of peptide-based neuropsychiatric therapeutics, alongside compounds like Selank and Semax that have been used in Russia for decades but remain investigational in Western markets. PE-22-28 is distinctive within this space because of its mechanistic grounding in humanin biology and glutamate homeostasis, which connects it to contemporary understanding of depression pathophysiology that emphasizes the role of glutamatergic signaling, astrocyte function, and neuroinflammation alongside the classical monoamine framework. The practical reality in April 2026 is that PE-22-28 remains a preclinical research peptide with limited published literature, no approved human use, no registered clinical trials, and a small but active self-experimentation community among biohackers interested in short peptide therapeutics for mood and cognitive applications. The compound is sold by research-chemical peptide vendors with the standard "for research purposes only" framing, and individual users have accumulated anecdotal experience with it in protocols typically involving daily or every-other-day subcutaneous dosing. The evidence base for PE-22-28 is substantially thinner than for BPC-157, Selank, or Semax in terms of published animal studies and translational groundwork; the peptide's profile rests on specific rodent behavioral studies and mechanistic biology inferred from its relationship to humanin and its proposed interactions with glutamate transporter regulation. This entry covers what is published about the peptide, the mechanistic rationale connecting it to humanin biology and glutamate homeostasis, the specific preclinical behavioral data that sparked interest in depression applications, realistic interpretation of that data in the context of the replication crisis in preclinical depression research, the theoretical and practical concerns with self-administration of a minimally characterized peptide, how PE-22-28 fits into the peptide stacking landscape alongside other cytoprotective and neuropsychiatric peptides, and what conservative thinking about this molecule looks like for someone considering it seriously rather than as a novelty.
How it works
PE-22-28 is a synthetic 7-amino-acid peptide (sequence GVSWGLR) and a shortened analog of spadin. Its proposed mechanism is inhibition of the TREK-1 (TWIK-related K+) channel, a two-pore-domain potassium channel (K2P2.1 / KCNK2) implicated in mood regulation. It is not related to humanin and is not a mitochondrial-derived peptide. Spadin itself (PE 12-28, a 17-amino-acid peptide) is a natural fragment released when sortilin - also called neurotensin receptor-3 (NTSR3) - is cleaved by furin to its mature form, liberating a 44-amino-acid propeptide (PE); spadin corresponds to residues 12-28 of that propeptide and blocks TREK-1 [PMID:20405001][PMID:30670975]. Working from spadin's blood-degradation products, Djillani and colleagues identified PE 22-28 (residues 22-28) as the shortest fragment that still blocks TREK-1, and found it is actually more potent and more selective than spadin, with an IC50 near 0.12 nM versus roughly 40-60 nM for spadin [PMID:28955242].
Read the full mechanismShow less
TREK-1 is a background ("leak") potassium channel that helps set and stabilize the resting membrane potential of neurons. In mice, genetic deletion of the TREK-1 gene produces a depression-resistant phenotype with enhanced serotonergic neurotransmission and increased hippocampal neurogenesis, which is the rationale for treating depression by pharmacologically blocking TREK-1 [PMID:28955242][PMID:25263033]. By inhibiting TREK-1, PE-22-28 is proposed to increase the firing of serotonergic neurons (spadin raised 5-HT firing in the dorsal raphe) and, over a few days, to drive hippocampal neurogenesis, cortical synaptogenesis (increased PSD-95), and a rapid rise in BDNF expression - the same downstream markers linked to spadin's fast-onset antidepressant action [PMID:28955242][PMID:20405001]. Importantly, in patch-clamp screens PE-22-28 was selective for TREK-1: it did not inhibit the related K2P channels TREK-2, TRAAK, TRESK or TASK-1, and it had no effect on the cardiac hERG channel, which the authors argue should limit off-target and cardiac liability [PMID:28955242]. All of this mechanistic evidence is preclinical (cell lines and mice); PE-22-28's targets, tissue distribution and blood-brain-barrier penetration have not been characterized in humans, so "proposed mechanism" remains a weaker claim than "demonstrated mechanism."
Benefits listed
- Antidepressant-like effects in rodent models of depression (preclinical only)
- Potent, selective inhibition of the TREK-1 (K2P2.1) potassium channel (IC50 ~0.12 nM)
- Rapid-onset (~4-day) antidepressant profile in animals, unlike the multi-week lag of SSRIs
- Increased hippocampal neurogenesis in mice
Show 2 moreShow less
- Increased cortical synaptogenesis (PSD-95) and BDNF expression in preclinical studies
- No human-validated benefits; not approved for any use (research use only)
02Research
Free with emailWhat the research shows
No research bench grades PE-22-28 yet. Benches compare compounds people pair, with the evidence for each.
Unlock the research summary
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- A summary of the key research
- Safety and side effects
- A link to the PubMed results
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
03Safety
PE-22-28 side effects and interactions
Side effects
Not in our record
Who should not use it
Contraindications
PE-22-28 has no human safety data and is not an approved medicine, so every "contraindication" below is precautionary and framed around its proposed target (the TREK-1 potassium channel) and the reality that it is used without medical supervision.
Read all the contraindications and cautionsShow less
Clinical depression is the central caution. Moderate-to-severe depression - especially with any suicidal ideation - is a serious medical condition that should be managed with evidence-based care (psychotherapy, approved antidepressants) under a clinician, not self-treated with a research-chemical peptide. PE-22-28 should never be used as a substitute for prescribed treatment or professional care, and anyone whose mood worsens should stop and seek help.
Bipolar-spectrum and psychotic-spectrum disorders warrant particular caution: any agent that shifts mood or neuronal excitability carries a theoretical risk of destabilization (mania/hypomania, mood cycling, or unpredictable effects in psychosis), and PE-22-28 has no data in these populations. Pregnancy and breastfeeding should be treated as absolute contraindications given the complete absence of developmental safety data, and it should not be used by children or adolescents.
Drug-interaction concerns are uncharacterized but plausible. Because the peptide's rationale involves TREK-1 blockade with downstream serotonergic and neurogenic effects, combining it with prescribed antidepressants (SSRIs, SNRIs, tricyclics, MAOIs) or with other centrally acting psychiatric drugs (lithium and other mood stabilizers, ketamine, memantine) could produce additive or unpredictable effects and should not be done without physician oversight. TREK-1 also has roles in pain, seizure threshold and cardiovascular tone, so people with epilepsy, significant cardiovascular disease, or recent stroke/head injury should avoid unsupervised use. Known hypersensitivity to peptide products or to any excipient (for example the bacteriostatic water used for reconstitution) is a contraindication. Finally, the practical contraindication is using PE-22-28 for a psychiatric indication without any clinical infrastructure to monitor progress or escalate care.
Interactions
3 pairings in our record: 3 with a caution.
SSRIs / SNRIs / other prescribed antidepressants
CautionPE-22-28's proposed TREK-1 blockade drives downstream serotonergic and neurogenic effects that overlap with how antidepressants work; additive or unpredictable interactions are possible and have never been studied. Do not combine without physician oversight, and never replace a prescribed antidepressant with it.
Ketamine and other NMDA-acting agents
CautionBoth target rapid-onset antidepressant pathways through different mechanisms (ketamine via NMDA/mTOR, PE-22-28 via TREK-1); combined effects on mood and CNS excitability are uncharacterized.
Spadin (parent peptide)
CautionPE-22-28 is a shortened analog of spadin acting on the same TREK-1 channel, so combining the two is mechanistically redundant and confounds any attempt to judge effects.
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
Need bloodwork before starting?
Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.
04Dosing
Free with emailPE-22-28 dosage and protocols
- Dose range
- 250-2000 mcg subcutaneous per dose (empirical research-chemical community range; no clinically validated human dose exists; effective preclinical rodent doses were far lower, ~3 mcg/kg).
- Dosing
- Once daily or every other day (research-chemical community protocols; no validated clinical dosing schedule).
Unlock the dosing protocols
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- Dose, how often and how long
- Beginner, intermediate and advanced protocols
- Reconstitution and handling notes
- Stacking notes
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
05Prices
PE-22-28 prices
1 listing from 1 vendor, opening in the Featured order.
- Pack prices
- $49.99
- Lowest per mg
- $5.00/mg
- Vendors
- 1
- Listings
- 1 (vial)
Prices as the vendors list them, last recorded 27 October 2026.
| Vendor | Product | Price | Buy |
|---|---|---|---|
PE-22-28 10 mg vial, 1 vial In stock | $5.00/mg $49.99 Lowest per mg | Buy PE-22-28 10 mg at Disguised Alpha |
Vendors selling PE-22-28(1: trust score, certificates, payment, shipping)
- Disguised Alpha1 listing, from $49.99
Trust Score 50/100, 0 of 36 certificate records read, pays by card, crypto, bank transfer, ships to the US, the EU, the UK
Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors
Price history(2 days with a recorded price)
06Chemistry
Chemistry and structure
- Molecular formula
- C141H237N43O40S
- Molecular mass
- 773.9 g/mol (average; molecular formula C35H55N11O9)
- Amino acid sequence
- GVSWGLR (Gly-Val-Ser-Trp-Gly-Leu-Arg) - an unmodified 7-residue peptide corresponding to residues 22-28 of the 44-amino-acid sortilin/neurotensin receptor-3 (NTSR3) propeptide. It is the C-terminal fragment of spadin (spadin = PE 12-28).
- Half-life
- Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242].
08Questions
Frequently asked questions
What is PE-22-28 and how is it related to spadin?
PE-22-28 is a synthetic 7-amino-acid peptide (sequence GVSWGLR) and a shortened analog of spadin. Spadin (PE 12-28) is a natural 17-amino-acid fragment released when the receptor sortilin (neurotensin receptor-3) is processed, and it blocks the TREK-1 potassium channel. Researchers found PE-22-28 among spadin's breakdown fragments and showed it is the shortest piece that still blocks TREK-1 - and is actually more potent and more selective than spadin. It has been studied only in cells and mice as a fast-acting antidepressant candidate. It is not related to humanin. [PMID:28955242]
Has PE-22-28 been tested in humans?
No. As of 2026 there are no published human trials of PE-22-28, no ClinicalTrials.gov registrations, and no human pharmacokinetic, safety or efficacy data. All evidence is preclinical (cell lines and mice), and all human use is self-experimentation with research-chemical vendor material. [PMID:28955242]
How does PE-22-28 work for depression?
Its proposed mechanism is blockade of the TREK-1 (K2P2.1) potassium channel. In mice, removing TREK-1 produces a depression-resistant, pro-serotonergic phenotype, so blocking the channel pharmacologically is thought to be antidepressant. PE-22-28 inhibits TREK-1 with an IC50 near 0.12 nM (more potent than spadin), and in rodents a few days of dosing increases hippocampal neurogenesis, cortical synaptogenesis and BDNF - a rapid-onset pattern unlike the multi-week lag of SSRIs. This is a plausible, preclinically supported mechanism, but human efficacy has not been demonstrated. [PMID:28955242][PMID:20405001]
What dose of PE-22-28 is typically used?
There is no clinically validated dose. Effective rodent doses were very low (around 3 micrograms per kilogram, injected). Research-chemical community protocols instead use fixed doses in the range of roughly 250-2000 micrograms per injection, subcutaneously, once daily or every other day - figures that are empirical and not derived from human studies. Because no human pharmacokinetic data exist, all of these numbers should be treated as unvalidated. [PMID:28955242]
How long before PE-22-28 effects are noticeable?
In rodents, the antidepressant-type effects and the neurogenesis that accompanies them developed over about 4 days of dosing rather than after a single dose, and the parent peptide's behavioral effect was relatively short-lived per dose. Community self-reports vary widely - some describe changes within days, others none at all. Any human onset timing is anecdotal, since there are no controlled human data. [PMID:28955242]
Is PE-22-28 safe for long-term use?
Unknown. There are no long-term safety data in humans and no extended toxicology studies. The preclinical appeal is that PE-22-28 was selective for TREK-1 and did not affect the cardiac hERG channel or several related potassium channels, and spadin analogs showed no obvious effects on pain, seizures or heart function in short rodent studies - but chronic TREK-1 blockade in humans has never been evaluated. Conservative community practice is to cycle rather than dose continuously. [PMID:28955242]
Can I combine PE-22-28 with my antidepressant medication?
Not without talking to the prescriber first. PE-22-28's proposed mechanism (TREK-1 blockade with downstream serotonergic and neurogenic effects) overlaps conceptually with how antidepressants act, so combining it with SSRIs, SNRIs, tricyclics, MAOIs, lithium, or ketamine could have additive or unpredictable effects that have never been studied. Do not stop or replace a prescribed medication with PE-22-28, and keep regular psychiatric follow-up. [PMID:28955242]
What are the main side effects of PE-22-28?
No side effects are documented in humans because no trials have been done. In practice the most concrete risks are those of any injected research peptide: injection-site reactions and flu-like symptoms from endotoxin/pyrogen contamination or from impure or mislabeled material. Paradoxical worsening of mood or anxiety is possible with any centrally acting compound, especially in people with bipolar or psychotic vulnerability. [PMID:28955242]
Can PE-22-28 be used for anxiety, not just depression?
It has only been studied as an antidepressant candidate in rodents; there are no controlled data for anxiety. TREK-1 does have roles in mood and neuronal excitability, so an effect on anxiety is conceivable, but community reports are mixed and unverified. Significant anxiety disorders should be treated with evidence-based care rather than an unvalidated peptide. [PMID:28955242]
Is PE-22-28 worth trying given the limited evidence?
That is a personal risk decision, and the honest answer is that the evidence is thin: promising, mechanistically coherent rodent data from a single research group, no human trials, and an unregulated supply chain of variable quality. For anyone with more than mild, subclinical mood complaints - and certainly for moderate-to-severe or unstable depression - established care (therapy, approved medication, sleep, exercise) is the appropriate path, and PE-22-28 is not a substitute. Anyone who does experiment should use tested material, keep expectations realistic, and be prepared to conclude it does nothing. [PMID:28955242]
How many vendors sell PE-22-28, and what does it cost per mg?
1 of the vendors BodyHackGuide tracks list PE-22-28 (1 listing). Among BodyHackGuide's PE-22-28 listings recorded as in stock with a milligram count, the lowest price per milligram is $5.00/mg at Disguised Alpha and the median is $5.00/mg. The PE-22-28 prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a PE-22-28 listing is dated 27 October 2026.
Which vendors have third-party COAs for PE-22-28 on file at BodyHackGuide?
BodyHackGuide holds 16 third-party certificate records for PE-22-28, from . No editor has read any of BodyHackGuide's 16 certificate records for PE-22-28. The laboratory named on BodyHackGuide's PE-22-28 certificate records is Freedom Diagnostics Testing, and the newest test date on them is 12 August 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.
